TG Therapeutics Raises $60m Following Combo Therapy Success In CLL

 
• By Joseph Haas
  
Winning, victory, success and surviving concept. Green board game pawn stand alone, the white rest fallen. Eliminating competitors. One against the others. Last man standing. Against all odds.
TG Therapeutics' U2 combo topped a comparator regimen for PFS in CLL patients

More from Clinical Trials

More from R&D